5-Fluorotryptamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
5-Fluorotryptamine (5-fluoro-T, 5-FT, or 5-F-T; code name PAL-284) is a serotonin receptor agonist and monoamine releasing agent of the tryptamine family.[1][2]
- 576-16-9
2711-58-2 (hydrochloride)
| Clinical data | |
|---|---|
| Other names | 5-Fluoro-T; 5-FT; 5-F-T; PAL-284; PAL284 |
| Drug class | Serotonin receptor agonist; Monoamine releasing agent |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H11FN2 |
| Molar mass | 178.210 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
5-FT is known to have affinity for the serotonin 5-HT1A and 5-HT2A receptors, with Ki values of 18 nM and 6.0–3,908 nM, respectively.[3][4][5] It is a full agonist of the serotonin 5-HT2A receptor, with an EC50 of 2.64 to 58 nM and an Emax of 110%.[2][4] The drug is also an agonist of the serotonin 5-HT1A receptor, with an EC50 of 129 nM.[4] 5-HT shows high affinity for the serotonin 5-HT2B and 5-HT2C receptors as well (Ki = 5.7 nM and 3.72 nM, respectively).[5] In addition to its serotonin receptor agonism, 5-FT is a serotonin–dopamine releasing agent (SDRA), with EC50 values for induction of monoamine release of 10.1 nM for serotonin, 82.3 nM for dopamine, and 464 nM for norepinephrine.[2] The drug is also a weak monoamine oxidase inhibitor (MAOI), with IC50 values of 13,200 nM for monoamine oxidase A (MAO-A) and 52,500 nM for monoamine oxidase B (MAO-B).[1][6]
Despite its serotonin 5-HT2A receptor agonism, 5-FT failed to induce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, suggesting that it may not have hallucinogenic effects in humans.[1][6]
Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives.[7][8][9][10][11][12][13] However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.[14][8][2][13]
History
5-FT was first described in the scientific literature by 1983.[15]